iStock/Getty Images
Coronavirus Conception Covid 19 Istock Getty

FDA Issues Authorization for Eli Lilly COVID-19 Treatment

Nov. 12, 2020
The antibody-based treatment for the recently-diagnosed is similar to one received by President Trump last month.

The Food and Drug Administration has issued an Emergency Use Authorization for Eli Lilly & Co.’s COVID-19 antibody treatment drug bamlanivimab.

According to Indianopolis-based pharmaceutical company Eli Lilly, the EUA is based on positive results from Phase 2 trials when used on patients with recently diagnosed COVID. The drug uses laboratory-made antibodies, proteins the body usually creates to fight off infections, to handicap the spread of the virus in the body.

Data from the ongoing study, says Daniel Skovronsky, President of Lilly Research Laboratories, show the drug may help patients clear the virus and reduce hospitalizations. The drug is conditionally approved for use in mild to moderate COVID cases, but not for those who have been hospitalized or are receiving oxygen therapy.

“We’re proud of the speed with which we have been able to bring patients this therapy specifically designed to treat COVID-19,” said Skovronsky.

"This emergency authorization allows us to make bamlanivimab available as a COVID-19 treatment for recently diagnosed, high-risk patients—adding a valuable tool for doctors fighting the now-increasing burden of this global pandemic," said David A. Ricks, CEO of Eli Lilly.

The U.S. has already purchased 300,000 doses of the treatment for $375 million and has promised that U.S. patients will not be charged for the medicine. The FDA grants emergency use authorizations to make promising drugs available to physicians for emergency cases before they receive full approval.

The drug is similar to the one produced by Regeneron Pharmaceuticals. Regeneron’s drug, which also uses antibodies to combat the virus, was administered to President Trump in October after the President was diagnosed with COVID. 

Popular Sponsored Recommendations

How Digital Twin Technology is Empowering Manufacturers

Sept. 27, 2023
This FAQ delves into why this technology offers business value and considerations toward implementation.

Digitally Transforming Data and Processes With Product Lifecycle Management

Oct. 29, 2023
Manufacturers face increasing challenges in product development as they strive to consistently deliver improved results. Discover how industry leaders are improving time-to-market...

Discover How an Eye Tracking Study Improves Training Procedures

Oct. 29, 2023
Did you know that your training processes can be streamlined by visualizing and analyzing key skills within your employee base? Find out how we use eye tracking to capture advanced...

Risk-Based Asset Management (RBAM): Accounting for Risk in Your Asset Management Strategy

Sept. 14, 2023
What if you could get more out of assets, reduce the risk of critical failures AND keep all your stakeholders happy? It’s called risk-based asset management, or RBAM, and it’ll...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!